mRNA-4157 (V940) / KEYTRUDA®
Adjuvant treatment for high-risk melanoma (post-resection)
Key Facts
Indication
Adjuvant treatment for high-risk melanoma (post-resection)
Phase
Approved
Status
Commercial/Phase 3 in other cancers
Company
About Moderna
Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. Its historic achievement was the rapid development and global commercialization of SPIKEVAX®, a COVID-19 vaccine that proved the platform's efficacy and scalability. The company's strategy leverages its validated mRNA platform, substantial financial resources, and commercial infrastructure to build a durable portfolio of vaccines and therapeutics, aiming to address a wide spectrum of diseases with high unmet need.
View full company profile